Monte Rosa Therapeutics, Inc. GLUE reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, while ...
New research shows how hard it can be to stop medications once they become routine, even after medical advice shifts.
The experimental weight-loss drug is a triple agonist and the first of its kind to reach a phase 3 clinical trial ...
GLP-1 weight-loss results vary widely, and eating patterns may help explain why some patients lose more weight than others.
Morgan Stanley met with Amgen management after Novartis's pelacarsen trial failure. The bank sees a real edge for AMGN's ...
The 50-page document outlines what the FDA would like to see as vendors submit their technologies for regulatory review. It ...
Spread the loveWhen it comes to weight loss, we’ve seen a lot of promises, a lot of fads, and a lot of disappointment. But ...
Announcing a new article publication for Cardiovascular Innovations and Applications. Coronary artery disease (CAD) remains ...
The Motley Fool on MSN
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.
Sept 24 (Reuters) - Drug developer Atavistik Bio said on Thursday it has signed a deal with Swiss drugmaker Roche potentially worth nearly $2 billion, including milestone payments, to develop oral ...
Medical researchers investigate a frequently used drug and report that it's less effective for older patients than previously ...
Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results